Cardiocast

Analysis shows ‘Devil’s bargain’ in cardiac arrest


 

The “Devil’s bargain” of epinephrine use in cardiac arrest plays out in a new analysis. Also this week, updated recommendations reflect maturation of transcatheter aortic valve replacement, a comparison of cardiovascular protection in type 2 diabetes drugs, and sweeping reductions in documentation requirements headline a new Medicare fee schedule proposal. Listen on iTunes.

Recommended Reading

Galectin-3: A new post-MI prognostic biomarker?
MDedge Internal Medicine
MI risk prediction after noncardiac surgery simplified
MDedge Internal Medicine
Serum troponin predicts cardiovascular death in early arthritis
MDedge Internal Medicine
Alirocumab’s benefit greater in diabetes patients: ODYSSEY Outcomes
MDedge Internal Medicine
DOJ lawsuit reins in inappropriate ICD use
MDedge Internal Medicine
Alteplase, aspirin provide similar functional outcomes after nondisabling stroke
MDedge Internal Medicine
Obesity triples post-MI sudden cardiac death risk
MDedge Internal Medicine
Older black patients die sooner after in-hospital cardiac arrest
MDedge Internal Medicine
Medicare’s bundled pay plan didn’t deliver big cost savings
MDedge Internal Medicine
Epinephrine for cardiac arrest: Better survival, more brain damage
MDedge Internal Medicine